Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 122

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 122
---
,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

On May 26, 2023, we completed
the closing of the May 2023 Registered Direct Offering, with institutional investors of (1) 166,017,700 Ordinary Shares represented by
16,601 Depositary Shares, issuable upon the exercise of the Series C Warrants at an exercise price of $400.00 per warrant, (2) 110,675,600
Ordinary Shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series D Warrants at an exercise price of $400.00
per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary Shares issuable upon the exercise of the May 2023 Placement
Agent Warrants at an exercise price of $375.00 per warrant.

On June 20, 2023 we issued
the Series C Warrants, Series D Warrants and placement agent warrants to the investors and the placement agent after receiving required
shareholder approval of the allotment of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under
the Series C Warrants, Series D Warrants and placement agent warrants at our general meeting held on June 14, 2023.

On December 21, 2023, in two
private placement transactions, we issued (i) an aggregate of 8,997 Depositary Shares to certain secured noteholders in satisfaction of
the Adhera Therapeutics, Inc., and (y) an aggregate of 90,999 pre-funded warrants to purchase Depositary Shares to certain of the secured
noteholders of Adhera Therapeutics, Inc., and (ii) issued to Melior Pharmaceuticals I, Inc. 14,177 of our Depositary Shares.

| II-1 |

On February 26, 2024, in connection with
our Company’s obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceuticals Co.
Ltd.

On April 29, 2024, in connection with the
closing of a Emtora License Agreement, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in